Mutations in a gene called CABLES1 might contribute to pituitary tumor growth in people with Cushing’s disease, according to a study that suggests the gene normally acts as a pituitary tumor suppressor. The study, “Loss-of-function mutations in the…
News
Five European countries have agreed to Verona Pharma’s plan to begin enrolling patients in a Phase 2b clinical trial of RPL554 as a maintenance treatment for chronic obstructive pulmonary disease, or COPD. The trial will be conducted in the United Kingdom, Germany, Romania, Bulgaria, and the Czech Republic. Verona expects to start…
The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently approved Daxas (roflumilast), developed by AstraZeneca, as a treatment for chronic obstructive pulmonary disease (COPD). The new indication could potentially benefit about 122,000 adults in the U.K. who are estimated to be eligible to receive Daxas, according…
The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health has granted $10 million to the McDonnell Genome Institute at Washington University to investigate and identify genes associated with chronic obstructive pulmonary disease (COPD) and other lung disorders in people from diverse ethnic backgrounds. Results of…
Recent Posts
- Fatigue, work limits may persist years after Cushing’s syndrome treatment
- Missing the symptoms of mild dehydration
- Japanese children face years-long delays in Cushing’s disease diagnosis
- What happens when I push past my limits with Cushing’s disease
- Long-term corticosteroid use caused Cushing’s in 5 patients: Report
- Stuck at the intersection of anxiety and insomnia
- Cushing’s syndrome greatly raises risk of hospitalization for infections
- Tumor cells left behind in surgery can cause Cushing’s recurrence, per report
- Building strength, even with Cushing’s, so I can be there for my daughter
- Corcept gives FDA new relacorilant data in resubmitted application